BSH/ISH 2016 | The consequences of epigenetic drugs in the treatment of AML
Charles Craddock
• 18 Apr 2016
Charles Craddock, CBE, FRCP, FRCPath, DPhil, from Queen Elizabeth Hospital, Birmingham, UK explains how epigenetic drugs may have a capacity to modulate the immune system post-transplant in acute myeloid leukemia (AML). By demethylating the FOXP3 promoter it may be able to accelerate Treg reconstitution post-allograft and thereby potentially suppressing graft versus host disease. Prof Craddock also discusses the clinical trial RICAZA (ISRCTN36825171) in which 40 patients post-transplant azacidine was well-tolerated. Recorded at the 2016 Annual Meeting of the British Society of Haematology (BSH) and International Society of Hematology (ISH), held in Glasgow, Scotland
